


## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Otsuki, et al.  
Appl. No. : 10/785,446  
Filed : February 23, 2004  
For : METHOD OF TREATMENT OF  
DISEASE USING AN  
ADENOSINE A1 RECEPTOR  
ANTAGONIST  
Examiner : Royds, Leslie A.  
Group Art Unit : 1614

CERTIFICATE OF EFS WEB  
TRANSMISSION

I hereby certify that this correspondence, and  
any other attachment noted on the automated  
Acknowledgement Receipt, is being transmitted  
from within the Pacific Time zone to the  
Commissioner for Patents via the EFS Web  
server on:

November 21, 2007

  
(Date)

Ned A. Israelsen, Reg. No. 29,655

## RESPONSE TO RESTRICTION REQUIREMENT

**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In Response to the Restriction Requirement mailed June 22, 2007, Applicants provisionally elect to prosecute claims directed to Group (II): methods for treating a cardiovascular disease comprising administration of an AA<sub>1</sub>RA and a beta blocker. Applicants also elect heart failure as a species of cardiovascular disease, KW-3902 as a species of AA<sub>1</sub>RA, and carvedilol as a species of beta blocker. Claims that read on this species include Claims 10-13, and new Claims 26-34. Applicants respectfully request consideration of the following remarks.

**Amendments to the Claims** are reflected in the listing of claims which begins on page 2 of this paper.

**Remarks/Arguments** begin on page 10 of this paper.